Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
6.500
+0.060 (+0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about C4 Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
July 06, 2023
Via
Benzinga
Nasdaq Edges Lower Following Fed Minutes; C4 Therapeutics Shares Jump
July 05, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones dropping around 100 points on Wednesday. The Dow traded down 0.30% to 34,316.70 while the NASDAQ fell 0.04% to 13,811.43....
Via
Benzinga
Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher
July 05, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 50 points on Wednesday. The Dow traded down 0.17% to 34,361.31 while the NASDAQ fell 0.14% to 13,797.72. The S&P 500,...
Via
Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
July 05, 2023
Via
Investor Brand Network
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May
July 05, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell...
Via
Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action
May 30, 2023
Via
Investor Brand Network
The Latest Analyst Ratings for C4 Therapeutics
May 30, 2023
Via
Benzinga
Looking Into C4 Therapeutics's Return On Capital Employed
May 18, 2023
Via
Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 05, 2023
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 05, 2023
Via
Benzinga
C4 Therapeutics Stock Is Surging: What's Going On?
July 05, 2023
C4 Therapeutics Inc (NASDAQ: CCCC) shares are rising Wednesday after the clinical-stage biopharmaceutical company announced the FDA cleared its investigational new drug (IND)
Via
Benzinga
Expert Ratings for C4 Therapeutics
May 08, 2023
Via
Benzinga
Recap: C4 Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
Where C4 Therapeutics Stands With Analysts
March 28, 2023
Via
Benzinga
Looking Into C4 Therapeutics's Return On Capital Employed
February 28, 2023
Via
Benzinga
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
July 05, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
June 20, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug
June 03, 2023
Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Additionally, Lynk Pharma of Hangzhou...
Via
Talk Markets
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
May 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 04, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 19, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 24, 2023
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
February 24, 2023
Via
Benzinga
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
February 23, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
February 08, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday
February 03, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
January 30, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 25, 2023
Via
Benzinga
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2023
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.